TB-500
TB-500 is a synthetic peptide fragment studied for its possible connection with cell movement, wound healing, and tissue recovery. It is based on a small section of thymosin beta-4, but research on the two substances should not be treated as interchangeable.
TB-500 AT A GLANCE
WHAT IS TB-500?
TB-500 is commonly identified as an acetylated seven-amino-acid peptide with the sequence Ac-LKKTETQ. This sequence corresponds to amino acids 17 through 23 of thymosin beta-4, a naturally occurring 43-amino-acid peptide found throughout the body.
The name TB-500 is sometimes used loosely for products described as full-length thymosin beta-4, creating confusion about exactly which substance is being discussed. Scientific and regulatory sources generally distinguish TB-500 as the shorter fragment. This difference matters because research involving the complete thymosin beta-4 molecule does not automatically show that TB-500 produces the same effects.
HOW DOES TB-500 WORK?
The TB-500 sequence comes from a region of thymosin beta-4 associated with actin, a protein that helps cells maintain their shape and move. Cell movement is an important part of several repair processes because skin cells, blood-vessel cells, and other specialized cells must travel toward an injured area.
Researchers have proposed that TB-500 may preserve some of the cell-migration and wound-repair activity associated with full-length thymosin beta-4. However, its biological activity has not been established through human trials. The FDA has also reported that available evidence is insufficient to confirm that the fragment promotes wound healing.
Areas of Research
TB-500 research explores whether a short section of thymosin beta-4 can retain biological activity connected with cell movement and tissue repair.
WOUND HEALING
Investigating whether the peptide influences the movement of cells needed to close and rebuild damaged tissue.
MUSCLE AND TENDON RECOVERY
Exploring possible effects on soft-tissue repair following strain, injury, or physical stress.
CELL MOVEMENT AND ACTIN
Studying how the LKKTETQ sequence interacts with processes involving actin and the internal structure of cells.
INFLAMMATION AND BLOOD VESSELS
Examining proposed effects on inflammatory signaling and the formation of blood vessels needed to support healing tissue.
Research Highlights
Much of the interest surrounding TB-500 comes from studies of full-length thymosin beta-4. Laboratory and animal research involving thymosin beta-4 has reported increased cell movement, blood-vessel formation, reduced inflammatory activity, and faster repair in models of skin, corneal, muscle, and cardiac injury. Full-length synthetic thymosin beta-4 has also been evaluated in early human studies, including research involving eye conditions and reduced blood flow to the heart.
Evidence specifically involving the seven-amino-acid TB-500 fragment is far more limited. In its 2026 review, the FDA found no clinical studies in which TB-500 was administered to humans and no in-vivo animal studies establishing its effectiveness for wound healing. The agency also identified an laboratory study in which TB-500 did not improve closure in a fibroblast scratch model. These findings do not eliminate every possible biological effect, but they show why results involving full thymosin beta-4 cannot simply be assigned to TB-500.
WHAT IS TB-500 MOST COMMONLY RESEARCHED FOR?
TB-500 is most commonly discussed in connection with wound healing, muscle recovery, tendon and ligament repair, inflammation, and the formation of new blood vessels. These areas largely reflect findings from thymosin beta-4 research rather than strong evidence involving TB-500 itself. Direct research is not currently sufficient to establish that the shorter fragment improves injury recovery or tissue healing in humans.
HOW DOES TB-500 FIT INTO PEPTIDE RESEARCH?
TB-500 helps researchers explore whether a short active region of a larger natural peptide can reproduce some of the original molecule’s biological activity. This is an important question in peptide science because smaller fragments may behave differently, interact with fewer targets, or lose activity found in the complete molecule. TB-500 also illustrates why the identity and amino-acid sequence of a research product matter when interpreting scientific evidence.
WHAT MAKES TB-500 UNIQUE?
TB-500 stands out because it is associated with a naturally occurring peptide that has several roles in cell structure and tissue repair, yet it contains only seven of that peptide’s 43 amino acids. Its sequence includes the LKKTET region connected with actin-related activity. Whether this small fragment retains enough of thymosin beta-4’s broader behavior to create meaningful effects remains uncertain.
HOW IS TB-500 DIFFERENT FROM BPC-157?
TB-500 and BPC-157 are both commonly discussed in tissue-repair research, but they come from different biological sources and have different proposed actions. TB-500 is a fragment based on thymosin beta-4 and is studied primarily in connection with actin, cell movement, and wound repair. BPC-157 is a 15-amino-acid synthetic peptide based on a sequence found in gastric juice and is researched for possible effects involving blood vessels, digestive tissue, tendons, and protective signaling. Neither is FDA approved, and direct human evidence remains extremely limited.
WHAT HAVE RESEARCHERS LEARNED ABOUT TB-500 SO FAR?
Researchers have learned a great deal about full-length thymosin beta-4, including its relationship with actin, cell migration, inflammation, and tissue repair. Far less is known about TB-500. The FDA found no human-exposure data, no established clinical benefit, and insufficient safety information for the fragment. Researchers therefore cannot assume that TB-500 shares the effectiveness or early safety findings reported for complete thymosin beta-4.
IS RESEARCH ON TB-500 CONTINUING TODAY?
Interest in TB-500 continues, particularly around wound healing, peptide metabolism, product identification, and anti-doping detection. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed TB-500-related substances for possible inclusion on the 503A Bulks List. That process concerns whether eligible pharmacies may compound a substance under certain conditions; it does not make TB-500 an FDA-approved medication. More direct laboratory, animal, and carefully controlled human research is still needed to determine its activity and safety.